NEWS
最新消息
-
Research2026/06/04Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
-
Social Charity2026/05/07
-
News2026/04/21Elixiron Immunotherapeutics Announces Signing of MOU with GEM Yield Bahamas Limited for up to NT$1.25 Billion in Investment!
-
News2026/03/10Elixiron Partners with CUORiPS to Target Immune Rejection in Allogeneic iPSC Transplantation.
-
Media2025/12/17Elixiron Immunotherapeutics Honored with National Innovation Award: Building an Evidence-Based Immunotherapy R&D Platform and Global Partnership Capabilities
-
News2025/12/10Elixiron Immunotherapeutics Pre-Listing Investor Conference
-
Statement Clarifying2025/12/04The Company Statement Clarifying Recent Market Speculations
-
Media2025/09/18Elixiron Targets T-Cell Exhaustion with 2026 Phase I Trial
-
Media2025/07/29Japan, Korea, and Taiwan Spotlight Innovative Alzheimer’s Therapies — Elixiron’s Enrupatinib Earns High Praise at International Forum, Pioneering a New Immunotherapy Option
-
Event2025/07/01Bio Asia Taiwan 2025 Corporate Presentation Highlights: A New Hope for Alzheimer’s Patients — Innovative Therapy from Elixiron Biotherapeutics
-
Media2025/06/12Immunotherapy Rising Star Elixiron Raises NT$1 Billion, Secures Rakuten Investment, and Targets Q4 Emerging Stock Board Listing
-
Media2025/05/18FISS 2025 Brings Together Leading Experts to Boost Taiwan’s Immunotherapy Research Capacity
